Exploring the effect of estrogen intake during menopause on the risk of breast cancer recurrence

Researchers at Odense University Hospital in Denmark show that postmenopausal estrogen replacement therapy does not increase the risk of breast cancer recurrence, even in estrogen-positive tumors.

Many doctors caution women with breast cancer against using hormone therapy during menopause. This is due to two tests conducted in the 1990s. Subsequent studies did not show an increase in relapses, but had serious limitations, including small sample sizes and short follow-up periods.

The study included women diagnosed with early-stage breast cancer between 1997 and 2004. Among them, three groups were distinguished: the first and second groups received hormone therapy vaginally (1957 women) or oral (133 women) for five years with At the beginning of the study, the third did not receive hormonal therapy (8461 women). The researchers found no increased risk of relapse or death in those who received hormone therapy during menopause.

While the study authors recommend caution and weigh the risks and benefits on a case-by-case basis, their findings may allow breast cancer survivors to provide relief from menopausal symptoms, including nighttime hot flashes, vaginal dryness, and urinary tract infections.

• For more: East Post ,for social media: East Post page